Teva Pharmaceutical (Israel) Management Performance Evaluation

TEVA -- Israel Stock  

ILS 7,940  98.00  1.22%

Analysis of Teva Pharmaceutical manpower and management performance can provide insight into Teva Pharmaceutical stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with Teva Pharmaceutical future performance. Also please take a look at World Market Map.

Teva Pharmaceutical Management Effectiveness

The company has return on total asset (ROA) of 2.82 % which means that it generated profit of $2.82 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (41.46) % meaning that it generated substantial loss on money invested by shareholders.

Teva Pharmaceutical Workforce Comparison

Teva Pharmaceutical Industries Limited is currently regarded as top stock in number of employees category among related companies. The total workforce of Drug Manufacturers - Specialty & Generic industry is at this time estimated at about 56,688. Teva Pharmaceutical totals roughly 51,792 in number of employees claiming about 91% of equities under Drug Manufacturers - Specialty & Generic industry.

Teva Pharmaceutical Profit Margins

The company has Profit Margin (PM) of (48.1) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 16.65 % which suggests for every 100 dollars of sales it generated a net operating income of 0.17.

Teva Pharmaceutical Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of seventeen. Teva Pharmaceutical Price Series Summation is a cross summation of Teva Pharmaceutical price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Teva Pharmaceutical Stakeholders

Carlo Notaristefani CEO of Global Operations and President of Global Operations
Erez Vigodman CEO and President Director and Member of Fin. and Invesment Committee
Sigurdur Olafsson President and CEO - Global Generic Medicines Group
Kaare Schultz President CEO
Robert Koremans President CEO-Global Specialty Medicines
Amir Elstein Vice Chairman of the Board
Richard Daniell Executive Vice President - European Commercial
Mark Sabag Group Executive Vice President Human Resources
Gianfranco Nazzi Executive Vice President - Growth Markets Commercial
Iris BeckCodner Group Executive Vice President - Corporate Marketing Excellence and Communication
Brendan OGrady Executive Vice President - North America Commercial
Michael Hayden President - Global Research and Development, Chief Scientific Officer
Dipankar Bhattacharjee Senior Vice President CFO Americas and Head of Finance Operations
Hafrun Fridriksdottir Executive Vice President and Presidentident of Global Generics R&D
Isaac Abravanel Group Executive Vice President Teva Corporate in Israel and Global Community Alliances, Director
Michael McClellan CFO, Executive Vice President
Kevin Mannix Vice President Head of Investor Relations
Sven Dethlefs Executive Vice President - Global Marketing & Portfolio
Eyal Desheh CFO and Group Executive VP
Richard Egosi Chief Legal Officer and Group Executive VP
Nechemia Peres Independent Director
Moshe Many Independent Director
Roger Abravanel Independent Director
Richard Lerner Independent Director
Galia Maor Independent Director
JeanMichel Halfon Statutory - independent director
Gabrielle Sulzberger Statutory Independent Director
Yitzhak Peterburg Director
Joseph Nitzani Independent Director
Perry Nisen Independent Director
Murray Goldberg Independent Director
Dan Propper Independent Director
Ory Slonim Independent Director
Dan Suesskind Director
Arie Belldegrun Independent Director
Sol Barer Director
Jean Halfon Statutory - independent director
Gerald Lieberman Director
Roberto Mignone Independent Director
Rosemary Crane Director
Timothy Wright Head - Business Development, Strategy and Innovation
David Stark Chief Legal Officer

Teva Pharmaceutical Leadership

Teva Pharmaceutical Top Executives

  Carlo Notaristefani  CEO
CEO of Global Operations and President of Global Operations
  Erez Vigodman  CEO
CEO and President Director and Member of Fin. and Invesment Committee

Teva Pharmaceutical Tenure Analysis

Teva Pharmaceutical Employment Tenure

Teva Pharmaceutical employes about 51792 people. The company is managed by 42 executives with total tenure of roughly 124 years, averanging almost 2.0 years of service per executive having 1233.0 employee per reported executive.

Teva PharmaceuticalManpower Efficiency

Return on Teva Pharmaceutical Manpower

Revenue Per Employee443 K
Revenue Per Executive494.8 M
Net Income Per Employee22.5 K
Net Loss Per Executive244.3 M
Working Capital Per Employee104.1 K
Working Capital Per Executive128.4 M

Per Employee

Teva Pharmaceutical Per Employee Growth Over Time

Net Income Per Employee

Revenue Per Employee

Also please take a look at World Market Map. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.
Search macroaxis.com